Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Extensive-stage Small Cell Lung Cancer (ES-SCLC) Clear all

Conditions: Small Cell Lung Cancer
Interventions: Tarlatamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Orlando, Florida • Grand Rapids, Michigan • Omaha, Nebraska

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 411
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more

Conditions: Small Cell Lung Carcinoma
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 22
States / cities: Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more

Conditions: Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Sacituzumab govitecan, Atezolizumab, Durvalumab; Drug
Lead sponsor: Bindu R Potugari; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Small-Cell Lung Cancer
Interventions: Durvalumab, AZD2811, Carboplatin, Cisplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Small-cell Lung Cancer
Interventions: Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Brian Henick, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Interventions: Tarlatamab, Durvalumab, Carboplatin, Etoposide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 50
States / cities: Casa Grande, Arizona • Goodyear, Arizona • Hot Springs, Arkansas + 45 more

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab, MK-4830, Boserolimab, Lenvatinib, Etoposide, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Gilbert, Arizona • Aurora, Colorado • Atlanta, Georgia + 10 more

Conditions: SCLC,Extensive Stage
Interventions: RYZ101 Dose Level -1, RYZ101 Dose Level 2, RYZ101 Dose Level 3, Atezolizumab, Carboplatin, Etoposide; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 9 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Extensive-Stage Small Cell Lung Cancer
Interventions: sunitinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Extensive Stage Lung Small Cell Carcinoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 561
States / cities: Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more

Conditions: Small Cell Lung Carcinoma
Interventions: coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more

Conditions: Extensive-Stage Small Cell Lung Cancer
Interventions: BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Lurbinectedin, Durvalumab; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 3 more

Conditions: Small Cell Lung Cancer
Interventions: YL201, Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Irvine, California • New Haven, Connecticut • Tampa, Florida + 7 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: Solid Tumor, Extensive-stage Small Cell Lung Cancer
Interventions: BNT411, Atezolizumab, Carboplatin, Etoposide; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Greenville, South Carolina

Conditions: NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate Cancer, HNSCC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Head Neck Cancer Squamous Cell Metastatic, ESCC or Esophageal Adenosquamous Carcinoma, CRC, CRC (Colorectal Cancer)
Interventions: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging); Drug
Lead sponsor: Aktis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Miami, Florida • Houston, Texas

Conditions: Small-Cell Lung Cancer
Interventions: Atezolizumab, Lurbinectedin, Carboplatin, Etoposide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Marietta, Georgia • Peoria, Illinois • Scarborough, Maine + 9 more

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated); Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 36
States / cities: Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more

Conditions: Relapsed/Refractory Small Cell Lung Cancer
Interventions: BMS-986525, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more

Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions: IDE-161, Pembrolizumab; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more

Search by objective public record fields.

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Study of AZD2811 + Durvalumab in ES-SCLC

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors